{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:07:55Z","timestamp":1725235675446},"reference-count":12,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.acuroe.2024.04.003","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T15:29:39Z","timestamp":1711985379000},"page":"487-489","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Why is it necessary to produce a BCG strain in Spain?"],"prefix":"10.1016","volume":"48","author":[{"given":"M.","family":"Unda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Cozar-Olmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Alvarez-Osorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2024.04.003_bib0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.eururo.2012.08.064","article-title":"Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer","volume":"63","author":"Thomas","year":"2013","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2024.04.003_bib0010","unstructured":"Red Espa\u00f1ola de Registros de C\u00e1ncer (REDECAN). hppts:\/\/stage.redecan.org. Last visit 19 Dec 2023."},{"key":"10.1016\/j.acuroe.2024.04.003_bib0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.juro.2013.08.049","article-title":"Bladder cancer in Spain 2011: population based study","volume":"191","author":"Mi\u00f1ana","year":"2014","journal-title":"J Urol."},{"key":"10.1016\/j.acuroe.2024.04.003_bib0020","unstructured":"European Association of Urology guidelines. [Accessed 19 Dec 2023] Available from: https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer."},{"key":"10.1016\/j.acuroe.2024.04.003_bib0025","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2009.11.023","article-title":"The role of Bacillus Calmette-Guerin in the treatment of non\u2013muscle-invasive bladder cancer","volume":"57","author":"Gontero","year":"2010","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2024.04.003_bib0030","unstructured":"Actualizaci\u00f3n del desabastecimiento de BCG polvo para suspensi\u00f3n intravesical. Available from: https:\/\/www.aemps.gob.es\/informa\/notasinformativas\/medicamentosusohumano-3\/problemasSuministro\/2014\/ni-muh_33-2014-bcg-polvo\/."},{"key":"10.1016\/j.acuroe.2024.04.003_bib0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.acuro.2013.04.002","article-title":"Tratamiento del tumor vesical no m\u00fasculo infiltrante frente al problema de disponibilidad de bacilo de Calmette-Guerin. Consenso de un panel de expertos espa\u00f1oles","volume":"37","author":"Fern\u00e1ndez-G\u00f3mez","year":"2013","journal-title":"Actas Urol Esp."},{"key":"10.1016\/j.acuroe.2024.04.003_bib0040","doi-asserted-by":"crossref","first-page":"15443","DOI":"10.1038\/srep15443","article-title":"Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations","volume":"5","author":"Abdallah","year":"2015","journal-title":"Sci Rep."},{"key":"10.1016\/j.acuroe.2024.04.003_bib0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clgc.2019.10.021","article-title":"Comparative effectiveness of intravesical BCG-Tice and BCG-Moreau in patients with non-muscle-invasive bladder cancer","volume":"18","author":"D\u2019Andrea","year":"2020","journal-title":"Clin Genitourin Cancer."},{"key":"10.1016\/j.acuroe.2024.04.003_bib0050","unstructured":"Clinicaltrials.gov\/study\/NCT03982797. Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis of Recurrence and Progression. [Accessed19 Dec 2023]."},{"key":"10.1016\/j.acuroe.2024.04.003_bib0055","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol."},{"key":"10.1016\/j.acuroe.2024.04.003_bib0060","doi-asserted-by":"crossref","unstructured":"Fernandez-Gomez JM, Unda-Urzaiz M, Alvarez-Ossorio JL, Cozar-Olmo JM. Br J Cancer Res. 2021;4:480-484. https:\/\/doi.org\/10.31488\/bjcr.165.","DOI":"10.31488\/bjcr.165"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578624000301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578624000301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T02:05:04Z","timestamp":1725156304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578624000301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2173578624000301"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2024.04.003","relation":{},"ISSN":["2173-5786"],"issn-type":[{"type":"print","value":"2173-5786"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why is it necessary to produce a BCG strain in Spain?","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2024.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2024.01.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}